Picture1.png
CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions
18. November 2024 08:00 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as it prepares to launch its specialized pharmaceutical a
Picture1.png
Cannabis Bioscience International Holdings Selected to Participate in DEA Hearing on Cannabis Rescheduling Docket No. 1362 and Hearing Docket No. 24-44
12. November 2024 08:00 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is honored to announce it was selected from a competitive field of numerous companies as one of
SABPrimaryLogoColorRGB900px72ppi.png
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
31. Oktober 2024 07:00 ET | SAB Biotherapeutics, Inc.
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
Picture1.png
CBIH Pursues Regulatory Compliance and Market Growth with Essential Licensing Applications
15. Juli 2024 08:00 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings (OTCMKTS:CBIH) has initiated a strategic move to expand its presence in the cannabis market by filing applicati
Picture1.png
CBIH Charts Path to Future Leadership in Cannabis Medicine
08. Juli 2024 08:00 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
A letter from our desk HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Since the start of the year, Cannabis Bioscience International Holdings (OTCMKTS: CBIH) has embarked on a transformative journey...
Picture1.png
CBIH advances Cancer Care with Novel Cannabis Patents for Breast and Pancreatic Cancers
01. Juli 2024 08:00 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatm
CBIH Announces Strategic Advancements Initiated by Recently Appointed Director, Setting a New Paradigm and Driving Visionary Change
26. Juni 2024 10:52 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
As CBIH prepares for the manufacturing and distribution of its products, the potential collaboration might involve this entity acting as CBIH's distributor
Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation
17. Juni 2024 09:50 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
CBIH a company dedicated to medicinal cannabis research for over 15 years, has achieved a 2 billion dollar valuation.
CBIH and Vita Biotech Forge Alliance to Propel Clinical Studies Forward
05. Juni 2024 15:12 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
“Collaboration in clinical trials ensures data integrity and safety, advancing both organizations' missions and improving patient care,” says Dr. Jennifer
SAB_Logo.png
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
02. Oktober 2023 07:30 ET | SAB Biotherapeutics, Inc.
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes